Jazz Pharmaceuticals Plc Stock Performance
| JAZZ Stock | USD 121.06 2.70 2.18% |
On a scale of 0 to 100, Jazz Pharmaceuticals holds a performance score of 9. The company retains a Market Volatility (i.e., Beta) of 0.67, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Jazz Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Jazz Pharmaceuticals is expected to be smaller as well. Please check Jazz Pharmaceuticals' treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day typical price , to make a quick decision on whether Jazz Pharmaceuticals' current trending patterns will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Jazz Pharmaceuticals PLC are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Jazz Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.5 | Five Day Return (1.27) | Ten Year Return (22.80) | All Time Return 598.03 |
1 | Disposition of 1000 shares by Bruce Cozadd of Jazz Pharmaceuticals at 110.84 subject to Rule 16b-3 | 11/01/2024 |
2 | Should Value Investors Buy Jazz Pharmaceuticals Stock | 11/19/2024 |
3 | Wall Street Analysts Think Jazz Could Surge 44.37 percent Read This Before Placing a Bet | 11/29/2024 |
4 | Jazz Up 3.4 percent Since Last Earnings Report Can It Continue | 12/06/2024 |
5 | CBD Drug For Tuberous Sclerosis Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements | 12/09/2024 |
6 | 5 High ROE Stocks to Buy as Volatility Weighs on Markets | 12/11/2024 |
7 | Zymeworks Hosts RD Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases | 12/12/2024 |
8 | Jazz Pharmaceuticals Announces CEO Succession Plan | 12/16/2024 |
9 | Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference | 12/17/2024 |
10 | Akari Therapeutics appoints new CEO and board member | 12/18/2024 |
11 | Debbies Dream Foundation Curing Stomach Cancer Celebrates a Year of Impactful Programs and Community Support in 2024 | 12/23/2024 |
| Begin Period Cash Flow | 881.5 M |
Jazz |
Jazz Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 10,852 in Jazz Pharmaceuticals PLC on October 5, 2024 and sell it today you would earn a total of 1,524 from holding Jazz Pharmaceuticals PLC or generate 14.04% return on investment over 90 days. Jazz Pharmaceuticals PLC is currently generating 0.2337% in daily expected returns and assumes 1.9287% risk (volatility on return distribution) over the 90 days horizon. In different words, 17% of stocks are less volatile than Jazz, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Jazz Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Jazz Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Jazz Pharmaceuticals PLC, and traders can use it to determine the average amount a Jazz Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1212
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | JAZZ | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.93 actual daily | 17 83% of assets are more volatile |
Expected Return
| 0.23 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Jazz Pharmaceuticals is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Jazz Pharmaceuticals by adding it to a well-diversified portfolio.
Jazz Pharmaceuticals Fundamentals Growth
Jazz Stock prices reflect investors' perceptions of the future prospects and financial health of Jazz Pharmaceuticals, and Jazz Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Jazz Stock performance.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0462 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 11.03 B | ||||
| Shares Outstanding | 60.45 M | ||||
| Price To Earning | 35.18 X | ||||
| Price To Book | 1.78 X | ||||
| Price To Sales | 1.86 X | ||||
| Revenue | 3.83 B | ||||
| Gross Profit | 3.39 B | ||||
| EBITDA | 1.23 B | ||||
| Net Income | 414.83 M | ||||
| Cash And Equivalents | 899.36 M | ||||
| Cash Per Share | 14.28 X | ||||
| Total Debt | 5.79 B | ||||
| Debt To Equity | 2.12 % | ||||
| Current Ratio | 3.16 X | ||||
| Book Value Per Share | 69.01 X | ||||
| Cash Flow From Operations | 1.09 B | ||||
| Earnings Per Share | 7.06 X | ||||
| Market Capitalization | 7.44 B | ||||
| Total Asset | 11.39 B | ||||
| Retained Earnings | 878.66 M | ||||
| Working Capital | 1.9 B | ||||
| Current Asset | 1.26 B | ||||
| Current Liabilities | 226.64 M | ||||
About Jazz Pharmaceuticals Performance
Evaluating Jazz Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Jazz Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Jazz Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 450.27 | 472.78 | |
| Return On Tangible Assets | 0.09 | 0.09 | |
| Return On Capital Employed | 0.07 | 0.06 | |
| Return On Assets | 0.03 | 0.03 | |
| Return On Equity | 0.13 | 0.22 |
Things to note about Jazz Pharmaceuticals PLC performance evaluation
Checking the ongoing alerts about Jazz Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Jazz Pharmaceuticals PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Jazz Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Jazz Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Debbies Dream Foundation Curing Stomach Cancer Celebrates a Year of Impactful Programs and Community Support in 2024 |
- Analyzing Jazz Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Jazz Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Jazz Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Jazz Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Jazz Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Jazz Pharmaceuticals' stock. These opinions can provide insight into Jazz Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Jazz Stock Analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.